Genome-Wide Tandem Repeat Expansions Modify Schizophrenia Risk in the Presence of a 22q11.2 Deletion

Why It Matters

Rare TREs explain a sizable portion of schizophrenia liability among 22q11.2 deletion carriers, offering new molecular targets for risk stratification and therapeutic research.

Key Takeaways

• Rare genic TREs increase schizophrenia risk in 22q11.2 deletion carriers
• TRE burden effect size comparable to polygenic risk score
• Intronic and splice‑adjacent TREs disrupt gene regulation in brain
• Affected genes include DLGAP2, SHANK2, DMPK linked to neurodevelopment

Pulse Analysis

The 22q11.2 deletion, present in roughly one in 2,000 live births, raises schizophrenia risk to about 25 %, making it a powerful natural model for dissecting the disorder’s genetics. While common polygenic risk and additional copy‑number variants have been implicated, they account for only a fraction of the penetrance gap. Tandem repeat expansions—segments of DNA that repeat in a head‑to‑tail fashion—constitute roughly 8 % of the human genome, yet their contribution to psychiatric disease has remained underexplored. By applying ExpansionHunter Denovo to whole‑genome data from 438 deletion carriers, the investigators uncovered a striking enrichment of rare, genic TREs among individuals with schizophrenia, especially in intronic and splice‑site regions where they can perturb transcriptional and splicing fidelity.

Statistical modeling revealed that each additional rare genic TRE raised the odds of schizophrenia by 1.7‑2.1‑fold, mirroring the influence of a standardized schizophrenia polygenic risk score. Functional annotation showed that these repeats frequently intersect brain‑specific quantitative trait loci for methylation and splicing, suggesting a mechanistic link to gene regulation. Genes hit by TREs—DLGAP2, SHANK2, DMPK, among others—are long, evolutionarily constrained, and converge on synaptic organization and neurodevelopmental pathways, echoing findings from GWAS and FMRP‑target studies. Single‑cell expression data further highlighted enrichment of TRE‑affected genes in excitatory and inhibitory neurons of the dorsolateral prefrontal cortex, a region central to schizophrenia pathology.

The discovery that rare TREs account for roughly 6‑9 % of schizophrenia liability in this high‑risk cohort reshapes our understanding of the disorder’s genetic architecture. It underscores the need to integrate repeat‑expansion profiling into routine genomic analyses for patients with known CNVs, potentially improving risk prediction and informing personalized interventions. Moreover, the overlap between TRE‑impacted genes and established schizophrenia pathways opens avenues for functional studies, drug target validation, and perhaps future therapies aimed at correcting repeat‑mediated dysregulation. As sequencing technologies become more affordable and analytical pipelines mature, TREs are poised to become a standard component of psychiatric genomics.